GT Biopharma series L preferred holders waive redemption rights permanently

GT Biopharma, Inc.

Holders of Series L 10% Convertible Preferred Stock waived redemption rights under Section 10 of the Certificate of Designations.
Waivers were provided on September 17, 18, and 23, 2025, and are permanent.
Waiver does not affect other rights of the preferred stockholders under the Certificate of Designations.
The company requested the waiver; certain holders countersigned the form of waiver.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

GT Biopharma, Inc. issued preferred stock to certain of the holders of GT Biopharma, Inc.'s Series L 10% Convertible Preferred Stock.

Security: preferred stock
Purchaser: certain of the holders of GT Biopharma, Inc.'s Series L 10% Convertible Preferred Stock

Exact text from the filing

each of September 17, 2025, September 18, 2025 and September 23, 2025, certain of the holders of GT Biopharma, Inc.’s Series L 10% Convertible Preferred Stock (the “Series L Preferred Stock”) provided a waiver (the “Waiver”) to the Certificate of Designation of Preferences, Rights and Limitations of Series L 10% Convertible Preferred Stock (the “Certificate of Designations”)

View on SEC.gov

26 equity issuances filed in the last 30 days. Browse all equity issuances →

GT Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-014684

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.